Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Raising Hope For Male Contraception

Blocking two proteins responsible for transporting sperm into the ejaculate may lead to a birth control pill for men

by Sarah Everts
December 9, 2013 | A version of this story appeared in Volume 91, Issue 49

The search for a male contraceptive pill has been stymied by two major problems: To date, most therapeutic strategies lead to either irreversible infertility or unwanted changes to male sexuality. Now, a research report suggests a new approach that could sidestep these problems. Sabatino Ventura of Australia’s Monash University and colleagues propose that scientists working on male contraceptives should focus on blocking the action of two proteins required for sperm to be transported from the vas deferens into semen during ejaculation (Proc. Natl. Acad. Sci. USA 2013, DOI: 10.1073/pnas.1318624110). The team, working with mice, first knocked out the genes for these proteins, called α1A-adrenergic G protein-coupled receptor and P2X1-purinoceptor ligand-gated ion channel. “This modification produced 100% infertility without effects on sexual behavior or function,” the researchers note. To determine the effect on male mice’s fertility, the team used sperm extracted from the knockout mice to successfully fertilize an egg. The loss of the two genes didn’t affect sperm production, only its transport. If the work is translatable from mice to men, molecules that block the action of the proteins could form the basis of a male pill.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.